Evidence map›Paper›PMID 19675677›Full record

ArticlePloS one2009

A nanoconjugate Apaf-1 inhibitor protects mesothelial cells from cytokine-induced injury.

Beatriz Santamaría, Alberto Benito-Martin, Alvaro Conrado Ucero, Luiz Stark Aroeira, Ana Reyero, María Jesús Vicent, Mar Orzáez, Angel Celdrán, Jaime Esteban, Rafael Selgas and 5 more

Open access · goldAbstract read
In one paragraph

Article in PloS one, 2009. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.

0numbers the graph read from it
0cells of the map it votes in
10citing papers in PubMed
2.9field-weighted citation impact, top 10% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

10 citing papers in PubMed, 38 citations in OpenAlex.

  1. Article
  2. Review
  3. Nanomedicines for kidney diseases.Kidney international · 2016
    Review
  4. Article
  5. TWEAK and the progression of renal disease: clinical translation.Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association · 2014
    Review
  6. Article
  7. Article
  8. Article
  9. Cell death assays for drug discovery.Nature reviews. Drug discovery · 2011
    Review
  10. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors at 5 institutions in 1 country.

Beatriz SantamaríaDialysis Unit, Fundación Jiménez Díaz, Universidad Autónoma de Madrid, Instituto Reina Sofía de Investigación Nefrológica, Madrid, Spain.
Alberto Benito-Martin
Alvaro Conrado Ucero
Luiz Stark Aroeira
Ana Reyero
María Jesús Vicent
Mar Orzáez
Angel Celdrán
Jaime Esteban
Rafael Selgas
Marta Ruíz-Ortega
Manuel López Cabrera
Jesús Egido
Enrique Pérez-Payá
Alberto Ortiz
Universidad Autónoma de Madrid · ESCentro de Investigacion Principe Felipe · ESHospital Universitario La Paz · ESHospital Universitario de La Princesa · ESHospital Universitario Fundación Jiménez Díaz · ES

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundInflammation may lead to tissue injury. We have studied the modulation of inflammatory milieu-induced tissue injury, as exemplified by the mesothelium. Peritoneal dialysis is complicated by peritonitis episodes that cause loss of mesothelium. Proinflammatory cytokines are increased in the peritoneal cavity during peritonitis episodes. However there is scarce information on the modulation of cell death by combinations of cytokines and on the therapeutic targets to prevent desmesothelization. METHODOLOGY: Human mesothelial cells were cultured from effluents of stable peritoneal dialysis patients and from omentum of non-dialysis patients. Mesothelial cell death was studied in mice with S. aureus peritonitis and in mice injected with tumor necrosis factor alpha and interferon gamma. Tumor necrosis factor alpha and interferon gamma alone do not induce apoptosis in cultured mesothelial cells. By contrast, the cytokine combination increased the rate of apoptosis 2 to 3-fold over control. Cell death was associated with the activation of caspases and a pancaspase inhibitor prevented apoptosis. Specific caspase-8 and caspase-3 inhibitors were similarly effective. Co-incubation with both cytokines also impaired mesothelial wound healing in an in vitro model. However, inhibition of caspases did not improve wound healing and even impaired the long-term recovery from injury. By contrast, a polymeric nanoconjugate Apaf-1 inhibitor protected from apoptosis and allowed wound healing and long-term recovery. The Apaf-1 inhibitor also protected mesothelial cells from inflammation-induced injury in vivo in mice.

conclusionCooperation between tumor necrosis factor alpha and interferon gamma contributes to mesothelial injury and impairs the regenerative capacity of the monolayer. Caspase inhibition attenuates mesothelial cell apoptosis but does not facilitate regeneration. A drug targeting Apaf-1 allows protection from apoptosis as well as regeneration in the course of inflammation-induced tissue injury.

Indexed as

EpitheliumAnimalsApoptotic Protease-Activating Factor 1Cells, CulturedCytokinesHumansMicePeritoneal DialysisAPAF1 protein, humanApaf1 protein, mouseApoptotic Protease-Activating Factor 1Cytokines

Identifiers

PMID19675677
PMCPMC2722088
OpenAlexW1988260454

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.